Stock Market news at lse.co.uk - RSS News Feeds

Glaxosmithkline Share News (GSK)



Share News for Glaxosmithkline (GSK)


Share Price: 1,773.00Bid: 1,767.50Ask: 1,768.00Change: 31.00 (+1.78%)Riser - Glaxosmithkline
Spread: 0.50Spread as %: 0.03%Open: 1,744.00High: 1,773.00Low: 1,734.00Yesterday’s Close: 1,742.00




Australian woman wins multi-million Thalidomide payout from Diageo

Wed, 18th Jul 2012 07:46

MELBOURNE, July 18 (Reuters) - An Australian woman has won a multi-million dollar payout from
UK company Diageo Plc, the local distributor of the drug Thalidomide that caused birth defects in thousand of babies around the world in the 1960s, her lawyers said on Wednesday.

Lynette Rowe, 50, was born without arms and legs after her mother Wendy took Thalidomide for a month while pregnant. At the time the drug was prescribed as a treatment for morning sickness.

The settlement with Rowe could pave the way for more than 100 other Thalidomide victims in Australia and New Zealand to receive compensation through a class action, the law firm Slater & Gordon said.

The drug was made by German company Grunenthal and was licensed in Australia to the firm Distillers, which was later taken over by Diageo. Grunenthal did not contribute to the settlement, the law firm said.

'Those pills that Wendy and thousands of women took 50 years ago have caused so much heartache and suffering, but at least something positive is now being done to put some things right,' Lynette's father Ian said in a statement released by Slater & Gordon.

Rowe's settlement follows a A$50 million ($51 million)payment Diageo agreed to make in 2010 to 45 Thalidomide victims in Australia and New Zealand, who sought help to cope with the mounting costs of care as they were living longer than expected.

'The approach announced today is both fair and equitable to all involved in this very sensitive and difficult situation,' said Diageo director Ian Wright.

Diageo had 'agreed a process that will explore resolution of as many of the remaining group claims as possible,' he said.

The cases have been closely watched in the United States, where a complaint has been filed against GlaxoSmithKline , Sanofi-Aventis, Avantor Performance Materials and Grunenthal, with several plaintiffs claiming their birth defects resulted from their mothers' use of Thalidomide.

The drug was widely used by pregnant women in Europe in the late 1950s and early 1960s to treat nausea, until evidence emerged that it caused terrible birth deformities.

That led to some countries, including Britain and Germany, setting up compensation systems for victims, but there was no such system in the United States, where the drug was never approved by the Food and Drug Administration but was used in clinical trials. ($1 = 0.9757 Australian dollars)



(Reporting by Aicha Marhfour; Editing by Daniel Magnowski) Keywords: THALIDOMIDE DIAGEO/

(Sonali.Paul@thomsonreuters.com)(+61 3 9286 1419)(Reuters Messaging: sonali.paul.thomsonreuters.com@reuters.net)

COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.







UPDATE 1-U.S. government taps GlaxoSmithKline for new antibiotics

* GSK to get up to $200 mln over five years under BARDA deal* Incentive for antibiotic R&D at time of rising resistanceBy Ben HirschlerLONDON, May 22
[7 Hours Ago]

U.S. government taps GlaxoSmithKline for new antibiotics

LONDON, May 22 (Reuters) - The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the
[9 Hours Ago]

Immune system cancer drugs tipped to be a $35 bln market

* Potential sales of $35 bln a year over next 10 years - Citigroup* Immunotherapy may be used in up to 60 percent of cancers* Bristol-Myers Squibb and
[11 Hours Ago]

UPDATE 3-Royalty raises Elan bid, issues ultimatum to shareholders

* Bid raised to $12.50/share from $11.25* Royalty will withdraw bid if shareholders back Elan deals* Reserves right to cut acceptance threshold to 50
[Mon 19:27]

UPDATE 3-XenoPort to drop multiple sclerosis drug, shares fall

* Drug does not show statistical significance compared with placebo* Co had stopped testing the drug to treat heartburn in 2011* Shares fall 26 pct
[Mon 16:25]

UPDATE 1-Chief executives and the itch to quit

By Andrew CallusLONDON, May 16 (Reuters) - On approaching his 60th birthday this year, long-serving Tullow Oil boss Aidan Heavey told staff he felt "l
[Thu 10:28]

Chief executives and the itch to quit

By Andrew CallusLONDON, May 16 (Reuters) - On approaching his 60th birthday this year, long-serving Tullow Oil boss Aidan Heavey told staff he felt "l
[Thu 07:08]

Bristol melanoma drug combo marks new advance in immunotherapy

(For more stories on new cancer data, see )By Julie SteenhuysenCHICAGO, May 15 (Reuters) - Melanoma patients treated with two Bristol-Myers Squibb dru
[15 May '13]



Sign up for Live Prices





Datafeed and UK data supplied by NETbuilder and Interactive Data. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.